RUNX1 and acute myeloid leukemia: Hamilton et al. [80] performed targeted NGS analysis on 112 AML patients who underwent alloHSCT; the most common mutations were TET2 (14.7%), FLT3 (12.9%), DNMT3A (12.1%), and Runt-Related Transcription Factor 1 (RUNX1) (7.8%).